PHA-543613

• Catalog No.: PZ0135
• CAS Number: 478149-53-0
• M. F.: C15H17N3O2
• M. W.: 271.31438
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide
• IUPAC Traditional name: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide
• Synonyms: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide

DATABASE IDS

• CAS Number: 478149-53-0

PROPERTIES

• Empirical Formula (Hill Notation): C15H17N3O2
• Purity: ≥98% (HPLC)
• Apperance: white to off-white powder
• Solubility: DMSO: ≥20 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H319
• GHS Precautionary statements: P305 + P351 + P338
• Storage Temperature: room temp
• German water hazard class: 1

DETAILS

Description (English)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
PHA-543613 is a potent selective α7 nAChR agonist. Nicotinic acetylcholine receptors are ligand-gated ion channels activated by nicotine, expressed in multiple tissues, with high functional expression in brain. The homomeric subtype α7 is a potential therapeutic target for cognitive deficits in schizophrenia and Alzheimer′s disease. PHA-543613 is active in both in vitro (binding, calcium flux, patch-clamp) and in vivo (auditory gating, novel object recognition) assays.

Description (简体中文)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
PHA-543613 is a potent selective α7 nAChR agonist. Nicotinic acetylcholine receptors are ligand-gated ion channels activated by nicotine, expressed in multiple tissues, with high functional expression in brain. The homomeric subtype α7 is a potential therapeutic target for cognitive deficits in schizophrenia and Alzheimer′s disease. PHA-543613 is active in both in vitro (binding, calcium flux, patch-clamp) and in vivo (auditory gating, novel object recognition) assays.